Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis.

Meyer, Julie A; DeChenne, Sharon; Foerder, Charles A; Hengel, Shawna M

Meyer, Julie A; DeChenne, Sharon; Foerder, Charles A; Hengel, Shawna M.

Afiliación

Meyer JA; Seagen Inc., Quantitative Pharmacology and Disposition, Bothell, WA 98021, USA.
DeChenne S; Alturas Analytics, Inc., Laboratory Department, Moscow, ID 83843, USA.
Foerder CA; Seagen Inc., Quantitative Pharmacology and Disposition, Bothell, WA 98021, USA.
Hengel SM; Seagen Inc., Quantitative Pharmacology and Disposition, Bothell, WA 98021, USA.

Bioanalysis ; 14(22): 1443-1452, 2022 Nov.

Article en En | MEDLINE | ID: mdl-36651218

A five-way cross-validation approach was successfully used to compare pharmacokinetic samples, tested using five different methods over twelve clinical trials, allowing combination of data and avoiding the need for multiple head-to-head method comparisons.

Asunto(s)

Neoplasias de la Mama; Espectrometría de Masas en Tándem; Humanos; Femenino; Espectrometría de Masas en Tándem/métodos; Neoplasias de la Mama/tratamiento farmacológico; Piridinas/uso terapéutico; Oxazoles

Palabras clave

HER2; bioanalysis; cross-validation; liquid chromatographytandem mass spectrometry; pharmacokinetic; tucatinib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Espectrometría de Masas en Tándem Idioma: En Revista: Bioanalysis Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google